AAO 2024: Applying large language models in revenue cycle management
October 22nd 2024In a presentation at the American Academy of Ophthalmology annual meeting in Chicago, T.Y. Alvin Lu, MD, a retina specialist at Johns Hopkins Medicine, discussed the application of large language models (LLMs) in revenue cycle management (RCM).
Read More
AAO 2024: New drug shows promise as first to protect vision in patients with dry AMD
October 21st 2024According to a study presented at the American Academy of Ophthalmology’s annual meeting in Chicago, investigational treatment reduced vision loss and protected key structures in the eye essential for vision.
Read More
AAO 2024: Chloroprocaine ophthalmic gel as anesthesia for intravitreal injections
October 21st 2024Michael Singer, MD, shared insights from on his experience using a preservative-free, chloroprocaine ophthalmic gel as anesthesia for intravitreal injections and the results of research on the effectiveness of gel versus traditional drops.
Read More
AAO 2024: Transient vision loss with Alexander Fein, MD
October 20th 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
Read More
Meghan Berkenstock, MD, an associate professor of ophthalmology at the Wilmer Eye Institute, provides insights on paper from the uveitis free paper section of AAO 2024, about the use of TriNetX database to assess for the incidence and prevalence of both uveitis and its complications.
Read More
AAO 2024: Defocus curve performance of trifocal IOLs and near activity vision questionnaire outcomes
October 20th 2024Adam Muzychuck, MD, FRCSC, sat down to discuss his presentation on the defocus curve performance of trifocal IOLs and the outcomes of the near activity vision questionnaire given to patients implanted with the Envy full range of vision IOL at this year's American Academy of Ophthalmology meeting held in Chicago, Illinois.
Read More
AAO 2024: Risk of posterior capsular rupture in second eye of patients with history of PCR
October 19th 2024Abdelrahman Elhusseiny, MD, MSc, sat down with David Hutton of Ophthalmology Times to discuss his presentation on the risk of posterior capsular rupture in fellow eyes of cataract surgery at this year's American Academy of Ophthalmology meeting being held in Chicago, Illinois.
Read More
AAO 2024: Centricity Vision to unveil new ZEPTOLink enhancements for improved efficiency and control
October 15th 2024Centricity Vision announced new ZEPTOLink enhancements, reducing treatment time by up to 60%. These updates, aimed at improving cataract surgery efficiency and control, will be showcased at the 2024 American Academy of Ophthalmology Annual Meeting in Chicago.
Read More
Oculis to present phase 3 DIAMOND program updates at Innovate Retina and Eyecelerator 2024
October 15th 2024David Eichenbaum, MD and Riad Sherif, MD, CEO of Oculis will present the updates with additional info on topline results from the ACUITY Phase 2 trial of OCS-05 for the treatment of acute optic neuritis (AON).
Read More
Rising diabetic retinopathy rates in youth signal potential public health crisis
October 13th 2024A recent paper reveals increasing rates of diabetic retinopathy in young patients with diabetes, sparking concerns over inadequate screening and management, especially among Black and Hispanic youths.
Read More
Nanoscope to submit BLA for MCO-010 to treat retinitis pigmentosa
October 10th 2024According to the company, MCO-010 is an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy for vision restoration in advanced retinitis pigmentosa (RP), irrespective of gene mutation.
Read More
Harrow relaunches triamcinolone acetonide injectable suspension
October 4th 2024Marketed as Triesence, it is a preservative-free synthetic corticosteroid that is approved by the FDA for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids.
Read More
Study: Socioeconomic inequality linked to increased risk of AMD
September 24th 2024Socioeconomic factors have long been a looming issue in various health outcomes. A team of researchers from Shanghai Jiao Tong University School of Medicine and Fudan University set out to review the impact of socioeconomic status inequality on the incidence of AMD.
Read More
ANI Pharmaceuticals completes acquisition of Alimera Sciences
September 17th 2024The acquisition strengthens the company’s rare disease segment, and adds 2 durable commercial assets, Iluvien and Yutiq with significant growth potential, expanding ANI’s foothold in strategic therapeutic area of ophthalmology.
Read More
Study: 100x improvement in sight detected after gene therapy trial
September 13th 2024According to research conducted by investigators at the Perelman School of Medicine at the University of Pennsylvania School of Medicine, patients with a rare inherited disease affecting their sight experienced quick vision improvements that sustained for the full year-long study.
Read More